The FDA has logged more than 1,700 adverse event reports tied to compounded semaglutide and tirzepatide combined, a figure that continues to grow amid ongoing FDA scrutiny of the GLP-1 compounding sector. The updated total reflects 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide, based on data through May 31, 2026.
The milestone arrives alongside a July 2026 JAMA Health Forum study that documented some compounders modifying formulations to circumvent the FDA’s ban on copying approved GLP-1 drugs. The FDA has separately stated that retatrutide and cagrilintide cannot be used in compounding under federal law, as neither is a component of an approved drug and neither has been found safe and effective for any condition.
What happened
The combined adverse event count surpassing 1,700 represents a material increase from earlier reporting that cited 990 reports for semaglutide and 730-plus for tirzepatide. The FDA has cautioned that these reports do not prove causation and likely undercount actual harms, a standard limitation of passive surveillance systems.
A JAMA Health Forum study published in July 2026 found that some compounding pharmacies are altering their formulations in ways that may sidestep FDA restrictions on copying commercially available approved drugs. The study characterized these formulation changes as a loophole in the agency’s enforcement approach. This was an independent research finding, not a new FDA statement.
Separately, the FDA confirmed its position that retatrutide and cagrilintide are not eligible for compounding under federal law. The agency’s reasoning is that neither substance is a component of an FDA-approved drug, and neither has been found safe and effective for any medical condition.
Why it matters
The rising adverse event count and documented evidence of formulation changes strengthen the FDA’s legal position in ongoing enforcement actions and court challenges related to GLP-1 compounding. For compounding pharmacies, 503B outsourcing facilities, and telehealth prescribers, these developments add to the regulatory and reputational risks associated with compounded GLP-1 products.
Patients using compounded GLP-1 medications are also affected. While the FDA notes that adverse event reports do not establish causation, the growing volume of reports raises patient safety questions that prescribers and compounders must factor into their risk assessments.
What to watch next
- Whether the FDA uses the JAMA Health Forum findings to support additional enforcement actions or rulemaking
- How compounders respond to the agency’s explicit position on retatrutide and cagrilintide
- Whether the adverse event count continues to rise in subsequent FDA reporting periods
- How telehealth platforms and prescribers adjust their practices in light of the updated safety data
Sources
Industry information only. Not medical or legal advice.
